modalities. Two clinical trials published in March 2023 show immunotherapy medications (pembrolizumab and dostarlimab) improve outcomes in patients ...
other cancers. These findings are available on BioRxiv. To study KSHV reactivation, Dr. Olson created a lytic replication indicator virus (KSHVLRI) by adding ...